---
schema_version: "secwatch.filing_event.v1"
accession: "0001082554-24-000037"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:14:51.411312+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics Q2 2024 revenue up 20% to $714.9M, EPS $5.85

## Summary
- Total revenues $714.9M (+20% YoY); net income $278.1M ($5.85 diluted EPS) vs $259.2M ($5.24) in Q2 2023.
- Tyvaso products revenue $398.2M (+25% YoY), led by Tyvaso DPI growth from PH-ILD launch.
- Remodulin $147.3M (+16%), Orenitram $107.1M (+13%), Unituxin $51.7M (+17%).
- R&D expense rose 57% to $139.6M, driven by upfront licensing payments and organ manufacturing.
- Completed $300M tranche of $1B ASR; final $700M settlement expected in Q3 2024.

## SEC filing metadata
- accession: 0001082554-24-000037
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000037/0001082554-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000108255424000037/uthr-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001082554-24-000037
- JSON: https://secwatch.observer/filing/0001082554-24-000037.json
- Plain text: https://secwatch.observer/filing/0001082554-24-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.